Introducing ROZIA-25 (Empagliflozin Tablets)
C & D Biosciences, a Division of R.P.P.L., is proud to announce the launch of ROZIA-25 (Empagliflozin Tablets 25 mg), the latest addition to its expanding portfolio of high-quality pharmaceutical products.
~Supports modern Type 2 Diabetes management with confidence
~Quality-assured Empagliflozin 25 mg formulation
~Manufactured under stringent international quality standards
~Backed by C & D Biosciences’ commitment to pharmaceutical excellence
DECODING ROZIA-25
Decoding ROZIA-25: The Science Behind the New Launch
ROZIA-25 contains Empagliflozin 25 mg, packed in 10*10 tablets, an SGLT2 inhibitor indicated for adults with Type 2 Diabetes Mellitus according to the approved prescribing information.
The launch of ROZIA-25 (Empagliflozin Tablets) demonstrates C & D Biosciences’ continued commitment to providing high-quality pharmaceutical solutions . Every tablet is manufactured with a focus on quality, consistency, and reliability, helping healthcare professionals deliver trusted diabetes care.
Why the Choice of ROZIA-25 ?
The introduction of ROZIA-25 (Empagliflozin Tablets) marks another significant milestone for C & D Biosciences in strengthening its diabetes care portfolio.
Key Features of ROZIA-25
~Empagliflozin 25 mg film-coated tablets
Our Commitment to Quality
At C & D Biosciences, quality is more than a standard—it is our commitment. Every product is developed with an emphasis on safety, consistency, regulatory compliance, and manufacturing excellence. The launch of ROZIA-25 (Empagliflozin Tablets) reflects our mission to provide dependable pharmaceutical solutions.
C & D Biosciences – Advancing Cardiac & Diabetic Care
As we continue to expand our range of Cardiac & Diabetic Care products, our focus remains on building lasting partnerships with healthcare professionals, distributors, stockists, and business associates while contributing to better patient outcomes through quality medicines.
C & D Biosciences – A Division of R.P.P.L. continues to move forward with a vision of delivering innovative, reliable, and quality-driven pharmaceutical solutions for a healthier tomorrow.
CONCLUSION
Conclusion
The launch of ROZIA-25 (Empagliflozin Tablets 25 mg) represents another important milestone in the journey of C & D Biosciences, a Division of R.P.P.L.
Disclaimer: ROZIA-25 should be prescribed and used only in accordance with the approved prescribing information. Healthcare professionals should evaluate individual patient requirements and follow applicable local regulatory guidelines.
Contact Us Today
Phone: +91 9592087880
Email: rouzelpharmapl@gmail.com
Website: www.rouzelpharma.in
